Sign inJoin waitlistJoin the waitlist

CM

Cara Mathews

Director, Gynecologic Oncology Research · Alpert Medical School

Credentials: · · · · · ·

History

Gynecologic Oncology Research · Alpert Medical School
Present
Women and Infants Hospital of Rhode Island
Present

Gynecologic Oncology
University of Oklahoma-Health Sciences Center
2012–2015
Obstetrics and Gynecology
Women & Infants Hospital
2008–2012
Internal Medicine
OU Health - OU Medical Center
2005–2008
Geisel School of Medicine at Dartmouth
2001–2005

Research

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
New England Journal of Medicine · 2018 · 2,290 citations
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
New England Journal of Medicine · 2023 · 633 citations
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Journal of Clinical Oncology · 2023 · 420 citations

CA
Carol Aghajanian
19 papers
Joan Walker
15 papers
Kathleen Moore
15 papers · 2 as a fellow
PD
Paul DiSilvestro
14 papers
Michael Gold
10 papers
Sharad Ghamande
8 papers
Joyce Liu
7 papers
Katherine Moxley
7 papers · 4 as a fellow
Matthew Powell
7 papers
RO
Roisin O'Cearbhaill
7 papers
RS
Russell Schilder
7 papers
David Mutch
6 papers

Clinical trials

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
Site PI · Recruiting · Phase 2
Aadi Bioscience, Inc.
2023–2027
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Site PI · Recruiting · Phase 1
National Cancer Institute (NCI)
2023–2027
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2022–2027
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Site PI · Recruiting · Phase 2
Acrivon Therapeutics
2022–2027